Patents by Inventor Jana Polivkova
Jana Polivkova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240140937Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: ApplicationFiled: November 28, 2023Publication date: May 2, 2024Applicant: Pfizer Inc.Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
-
Patent number: 11866425Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: GrantFiled: June 11, 2021Date of Patent: January 9, 2024Assignee: Pfizer Inc.Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
-
Publication number: 20230174532Abstract: Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I: or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.Type: ApplicationFiled: January 31, 2023Publication date: June 8, 2023Applicant: Pfizer Inc.Inventors: Christopher Ryan BUTLER, Michelle Renee GARNSEY, Kevin Alexander OGILVIE, Jana POLIVKOVA, Matthew Forrest SAMMONS, Aaron Christopher SMITH, Qingyi Yang
-
Patent number: 11643412Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.Type: GrantFiled: June 8, 2021Date of Patent: May 9, 2023Assignee: Pfizer Inc.Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
-
Publication number: 20230019853Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.Type: ApplicationFiled: June 8, 2021Publication date: January 19, 2023Applicant: Pfizer Inc.Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
-
Publication number: 20210309646Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: ApplicationFiled: June 11, 2021Publication date: October 7, 2021Applicant: Pfizer Inc.Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
-
Patent number: 11034678Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: GrantFiled: February 18, 2020Date of Patent: June 15, 2021Assignee: Pfizer Inc.Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
-
Publication number: 20200181127Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: ApplicationFiled: February 18, 2020Publication date: June 11, 2020Applicant: Pfizer Inc.Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
-
Publication number: 20180258081Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: ApplicationFiled: May 11, 2018Publication date: September 13, 2018Applicant: Pfizer Inc.Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
-
Patent number: 10071992Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: GrantFiled: August 11, 2017Date of Patent: September 11, 2018Assignee: Pfizer Inc.Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
-
Publication number: 20180051012Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: ApplicationFiled: August 11, 2017Publication date: February 22, 2018Applicant: Pfizer Inc.Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
-
Patent number: 9738626Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.Type: GrantFiled: December 16, 2015Date of Patent: August 22, 2017Assignee: Pfizer Inc.Inventors: Kevin Bahnck, Daniel Canterbury, David James Edmonds, Kentaro Futatsugi, Esther Cheng Yin Lee, Elnaz Menhaji-Klotz, Jana Polivkova, Robert Vernon Stanton
-
Publication number: 20160176851Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.Type: ApplicationFiled: December 16, 2015Publication date: June 23, 2016Applicant: Pfizer Inc.Inventors: Kevin Bahnck, Daniel Canterbury, David James Edmonds, Kentaro Futatsugi, Esther Cheng Yin Lee, Elnaz Menhaji-Klotz, Jana Polivkova, Robert Vernon Stanton
-
Patent number: 6992101Abstract: The present invention provides compounds of formula (I) the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein R?, R?, R??, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof in treating diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia.Type: GrantFiled: November 6, 2003Date of Patent: January 31, 2006Assignee: Pfizer, Inc.Inventors: Donald L. Bussolotti, Ronald B. Gammill, Jana Polivkova
-
Publication number: 20040157907Abstract: The present invention provides compounds of formula (I) 1Type: ApplicationFiled: November 6, 2003Publication date: August 12, 2004Applicant: Pfizer IncInventors: Donald L. Bussolotti, Ronald B. Gammill, Jana Polivkova
